Browse Health


Education ?

Medical School Score
University of New England (1985)

Awards & Distinctions ?

Patients' Choice Award (2014)
Compassionate Doctor Recognition (2014)
Umdnj-new Jersey Medical School
American Urological Association

Affiliations ?

Dr. Sussman is affiliated with 23 hospitals.

Hospital Affiliations



  • Kennedy Memorial Hospital -Umc - Stratford
    113 E Laurel Rd, Stratford, NJ 08084
    Top 25%
  • Virtua West Jersey Hospital - Berlin
    94 Brick Rd, Marlton, NJ 08053
    Top 50%
  • Kennedy Memorial Hospital-Umc-Cherry Hill
    2201 Chapel Ave W, Cherry Hill, NJ 08002
  • South Jersey Health System-Elmer
    500 Front St, Elmer, NJ 08318
  • Virtua West Jersey Hospital - Voorhees
    94 Brick Rd, Marlton, NJ 08053
  • Virtua Memorial Hospital Of Burlington County
    175 Madison Ave, Mount Holly, NJ 08060
  • Virtua West Jersey Hospital - Marlton
    94 Brick Rd, Marlton, NJ 08053
  • Kennedy University Hospital – Washington Township
    435 Hurffville Cross Keys Rd, Blackwood, NJ 08012
  • Summit Surgical Center
  • South Jersey Hospital - Bridgeton
    333 Irving Ave, Bridgeton, NJ 08302
  • Kennedy Health Systems
    18 E Laurel Rd, Stratford, NJ 08084
  • Virtua West Jersey Health System
  • Kennedy Memorial Hospital
  • Virtua WJ Hospital Marlton
  • South Jersey Healthcare - Elmer Hospital
    501 Front St, Elmer, NJ 08318
  • Kennedy Health Systems Stratford Division
  • Kessler Memorial HospitalHammonton, Nj
  • Kennedy Health Systems Cherry Hill Division
  • Virtua Health-Voorhees Division
  • Kessler Memorial Hospital
  • Virtua WJ Hospital Voorhees
  • Kennedy Health Systems Washington Township
  • Virtua Health-Marlton Division
  • Publications & Research

    Dr. Sussman has contributed to 6 publications.
    Title Effect of Tolterodine Extended Release with or Without Tamsulosin on Measures of Urgency and Patient Reported Outcomes in Men with Lower Urinary Tract Symptoms.
    Date September 2008
    Journal The Journal of Urology

    PURPOSE: We evaluated the efficacy of tolterodine extended release and/or tamsulosin on micturition related urgency episodes, urgency severity and patient reported outcomes in men who met entry criteria for prostatic enlargement and overactive bladder trials. MATERIALS AND METHODS: Men 40 years old or older with an International Prostate Symptom Score of 12 or greater, frequency (8 or more voids per 24 hours) and urgency (3 or more episodes per 24 hours) with or without urgency urinary incontinence were randomized to placebo, 4 mg tolterodine extended release, 0.4 mg tamsulosin or tolterodine extended release plus tamsulosin for 12 weeks. Subjects completed 5-day diaries; the Patient Perception of Bladder Condition and Urgency Perception Scale at baseline, and weeks 1, 6 and 12; Overactive Bladder Questionnaire at baseline, and weeks 6 and 12; Perception of Treatment Satisfaction question at weeks 1, 6 and 12; and Willingness to Continue question at week 12. Subjects rated the urgency associated with each micturition on a 5-point scale and micturition related urgency episodes were those rated 3 or greater. Urgency severity was measured using frequency-urgency sum, defined as the sum of urgency ratings for all micturitions. RESULTS: Compared with placebo, tolterodine extended release plus tamsulosin significantly reduced daytime and nocturnal micturition related urgency episodes as well as frequency-urgency sum at weeks 1, 6 and 12. It also improved Patient Perception of Bladder Condition scores at weeks 1, 6 and 12; improved Urgency Perception Scale and Overactive Bladder Questionnaire, Symptom Bother and Health Related Quality of Life scores at weeks 6 and 12; and increased the percentage of subjects who reported treatment satisfaction at weeks 6 and 12, and willingness to continue at week 12. CONCLUSIONS: Treatment with tolterodine extended release plus tamsulosin significantly improved urgency variables and patient reported outcomes in men meeting entry criteria for overactive bladder and prostatic enlargement trials.

    Title Overactive Bladder: Treatment Options in Primary Care Medicine.
    Date October 2007
    Journal The Journal of the American Osteopathic Association

    Overactive bladder is a highly prevalent condition, affecting approximately 33 million adults in the United States. Despite the considerable impact this condition has on patients' quality of life, overactive bladder remains underrecognized and undertreated as a result of patient embarrassment and reluctance to seek medical help, as well as a lack of proactive questioning by physicians. The present article encourages physicians to initiate a dialogue with patients regarding urinary control and, specifically, overactive bladder. Treatment options for overactive bladder recommended in the current article include both nonpharmacologic and pharmacologic therapies. Properties of antimuscarinic agents, including three new drug therapies, are reviewed and provided for physicians to optimize therapy options, particularly among elderly patients.

    Title Onset of Efficacy of Tolterodine Extended Release in Patients with Overactive Bladder.
    Date April 2007
    Journal Current Medical Research and Opinion

    OBJECTIVE: To assess the onset of efficacy of tolterodine extended release (ER) in patients with overactive bladder (OAB). RESEARCH DESIGN AND METHODS: A post hoc analysis was conducted using 3-day bladder diary data from a 12-week, multicenter, prospective, open-label study of tolterodine ER (4 mg qd) in patients (aged > or = 18 years) with urinary frequency (> or = 8 micturitions/24 h) and urgency (strong and sudden desire to urinate) with or without urgency urinary incontinence (UUI). MAIN OUTCOME MEASURES: Changes in micturition frequency, urgency, and UUI episodes/24 h were evaluated for treatment Days 5, 6, and 7. The percentages of patients who achieved normal micturition frequency (< 8/day) and 50%, 70%, 90%, and 100% reductions in urgency and UUI episodes (i.e., responders) were determined at Days 5, 6, and 7. Week 12 data are presented as a referent for the magnitude of treatment efficacy during Week 1. RESULTS: This analysis included 698 patients. On Day 5, there were significant reductions in all three diary variables (all p < 0.0001), and improvements continued on Days 6 and 7. More than half of the patients reported > or = 50% reductions in urgency or UUI episodes on Day 5. Responder rates for all three symptoms increased through Week 12. CONCLUSIONS: Patients with OAB experienced significant reductions in OAB symptoms as early as Day 5 of treatment with tolterodine ER. These data extend the findings of a previous analysis, in which all 3 days of the bladder diary were pooled, that demonstrated improvements in micturition frequency, urgency episodes, and UUI episodes in patients with OAB after 1 week of treatment with tolterodine ER. Limitations are that efficacy was not assessed before Day 5, this was a post hoc analysis, and the study was not placebo-controlled.

    Title Contemporary Treatment Options for Overactive Bladder.
    Date December 2005
    Journal Jaapa : Official Journal of the American Academy of Physician Assistants
    Title Pharmacokinetics, Pharmacodynamics, and Efficacy of Phosphodiesterase Type 5 Inhibitors.
    Date May 2004
    Journal The Journal of the American Osteopathic Association

    Clinical evidence in men with erectile dysfunction (ED) shows that the phosphodiesterase type 5 (PDE5) inhibitors sildenafil citrate, tadalafil, and vardenafil hydrochloride have favorable safety and efficacy profiles. However, as mild vasodilators, the PDE5 inhibitors are also associated with hemodynamic effects that may be clinically significant, especially when treating men with ED who have comorbid cardiovascular disease. Hemodynamic studies have shown that therapeutic dosages of the PDE5 inhibitors produce only mild and transient changes in mean systolic and diastolic blood pressure and heart rate in healthy men as well as those with ischemic heart disease or chronic stable angina. Overall, PDE5 inhibitors are safe and effective in most patient populations, including men with ischemic cardiovascular disease or those receiving anti-hypertensive agents, and men with diabetes or those who have undergone nerve-sparing retropubic radical prostatectomy. With the entry of three novel PDE5 inhibitors into the therapeutic armamentarium for ED, differentiating properties of the new agents may confer clinical benefits that physicians as well as patients and their partners should consider when selecting a PDE5 inhibitor.

    Title A Current Review of Medical Therapy for Benign Prostatic Hyperplasia.
    Date April 2004
    Journal The Journal of the American Osteopathic Association

    Benign prostatic hyperplasia (BPH) is one of the most common diseases of aging men. It is estimated that by age 60 years, greater than 50% of men will have histologically documented evidence of the disease. Therapy for this disease has evolved considerably from its inception. Recent data from long-term population-based studies have shed new light on the treatment of this common problem in aging men. The authors review the current state of diagnosis of BPH and medical therapy for this condition in the primary care setting.

    Similar doctors nearby

    Dr. Robert Barsky

    31 years experience
    Sewell, NJ

    Dr. Jeffrey Murray

    Sewell, NJ

    Dr. Jerome Pietras

    40 years experience
    Sewell, NJ

    Dr. Thomas Mueller

    9 years experience
    Sewell, NJ

    Dr. Gordon Brown

    14 years experience
    Sewell, NJ

    Dr. Marcella Nachmann

    21 years experience
    Sewell, NJ
    Search All Similar Doctors